Strickler, J. H., Raimbourg, J., Ghiringhelli, F., Cohen, J. E., Kitagawa, C., Sharma, M. R., … Kuboki, Y. (2024). 1439P ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study. In Annals of Oncology (Vol. 35, pp. S895–S896). Elsevier BV. https://doi.org/10.1016/j.annonc.2024.08.1505

Strickler, J. H., J. Raimbourg, F. Ghiringhelli, J. E. Cohen, C. Kitagawa, M. R. Sharma, K. H. Lee, et al. “1439P ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study.” In Annals of Oncology, 35:S895–96. Elsevier BV, 2024. https://doi.org/10.1016/j.annonc.2024.08.1505.

Strickler JH, Raimbourg J, Ghiringhelli F, Cohen JE, Kitagawa C, Sharma MR, et al. 1439P ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study. In: Annals of Oncology. Elsevier BV; 2024. p. S895–6.

Strickler, J. H., et al. “1439P ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study.” Annals of Oncology, vol. 35, Elsevier BV, 2024, pp. S895–96. Crossref, doi:10.1016/j.annonc.2024.08.1505.

Strickler JH, Raimbourg J, Ghiringhelli F, Cohen JE, Kitagawa C, Sharma MR, Lee KH, De Miguel M, Hunter ZN, Burns M, Li RR, Rudraganguly N, Biesdorf de Almeida C, Freise KJ, Blaney ME, Morrison-Thiele G, Neagu Aristide MR, Kuboki Y. 1439P ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study. Annals of Oncology. Elsevier BV; 2024. p. S895–S896.